MeiraGTx Q1 net loss $46.3M; reacquires bota-vec from J&J; raises $100M

MeiraGTx Holdings plc

Net loss attributable to ordinary shareholders was $46.3M ($0.57 per share) for Q1 2026, vs $40.0M ($0.51) in Q1 2025.
Cash and cash equivalents were $71.5M at March 31, 2026; subsequent $100M equity offering and $25M upfront payment to J&J for bota-vec.
Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 for radiation-induced xerostomia; positive 3-year data from Phase 1 AQUAx study.
Appointed Penny Fleck as Chief Development Officer; Stuart Naylor as Chief Scientific Officer, Ophthalmology.
Reacquired full rights to bota-vec for XLRP from J&J with $25M upfront plus milestones and mid-teens royalties.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

MeiraGTx Holdings plc reported financial results for first quarter ended March 31, 2026.

Period: first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 14, 2026, MeiraGTx Holdings plc (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

View on SEC.gov

Browse all earnings releases →

MeiraGTx Holdings plc filing history →

Source: SEC EDGAR

accession 0001104659-26-060726

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.